|
|
News Breaks | | | | December 19, 2012 | | 09:32 EDT |  | OGXI | OncoGenex announces initiation of Phase 2 OGX-427 study with Zytiga
OncoGenex Pharmaceuticals announced the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer who are experiencing a rising PSA while receiving Zytiga. The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay treatment resistance. The primary objective will be to compare the two treatment groups for delaying further disease progression while on Zytiga by assessing the progression-free survival rate at 60 days after adding OGX-427. Secondary objectives include comparing the treatment arms for PSA responses, objective responses, time to progression, circulating tumor cells and other biomarkers. | |
|
News For OGXI From The Last 14 Days Check below for free stories on OGXI the last two weeks. |
|
|
| May 23, 2013 | | 07:12 EDT | | OGXI | OncoGenex plans initiation of Ceder clinical trial for OGX-427
OncoGenex Pharmaceuticals announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the seventh randomized Phase 2 clinical trial evaluating OGX-427 in the treatment of advanced cancers and will investigate whether adding OGX-427 to gemcitabine and carboplatin therapy can extend progression-free survival, or PFS, outcomes. Cedar will randomize approximately 140 patients to receive either OGX-427 plus gemcitabine and carboplatin therapy, or gemcitabine and carboplatin therapy alone. The primary objective will be PFS, with secondary objectives to evaluate tumor response rates, overall survival, safety, tolerability, and health-related quality of life. Additional analyses will be conducted to determine the effect of therapy on heat shock protein 27 levels and to explore potential biomarkers that may help predict response to treatment. | | | May 22, 2013 | | 07:35 EDT |  | OGXI | Bloom Burton & Co. to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
